Short answer
Cartesian Therapeutics, Inc. (RNAC) filed an 8-K current report with the SEC on May 26, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). $50M funded initially within $150M senior secured term-loan capacity; additional $50M milestone-based and up to $50M discretionary.
Cartesian Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $50M funded initially within $150M senior secured term-loan capacity; additional $50M milestone-based and up to $50M discretionary
- Variable interest rate at least 8.95%, with maturity June 1, 2030 and amortization beginning July 1, 2029
- Lenders may convert up to $15M into equity, creating potential dilution subject to 19.99% aggregate and 9.985% ownership caps
- First-priority liens on substantially all assets excluding intellectual property, increasing creditor claims in a downside scenario
- Cash covenant begins April 2027; $40M trailing three-month product-revenue covenant begins January 2029
Item 5.02 · Departure/Election of Directors or Officers
- Chief Medical Officer Milos Miljkovic, M.D. resigning effective May 31, 2026
- Separation package includes six months’ salary and pro-rated bonus eligibility
- Continued medical, dental, and vision coverage available for up to six months
- Departure creates leadership transition risk for Cartesian’s clinical development programs
Item 7.01 · Regulation FD Disclosure
- May 26, 2026 press release disclosed details of the Company’s Loan Agreement
- Corporate slide presentation provides investors with current business updates and summaries
- Loan Agreement terms and strategic implications require review of Exhibit 99.1
- Business outlook and pipeline context require review of Exhibit 99.2
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cartesian Therapeutics, Inc. 8-K filings
Get the next RNAC 8-K as it lands
Follow RNAC for push alerts, or ask the research agent what this filing means.